157 related articles for article (PubMed ID: 12867067)
1. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Mack PC; Davies AM; Lara PN; Gumerlock PH; Gandara DR
Lung Cancer; 2003 Aug; 41 Suppl 1():S89-96. PubMed ID: 12867067
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
[TBL] [Abstract][Full Text] [Related]
4. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
Edelman MJ
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
[TBL] [Abstract][Full Text] [Related]
5. Use of proteasome inhibition in the treatment of lung cancer.
Schenkein DP
Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
[TBL] [Abstract][Full Text] [Related]
6. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
7. Sequencing bortezomib with chemotherapy and targeted agents.
Adjei AA
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
[TBL] [Abstract][Full Text] [Related]
8. Potential for proteasome inhibition in the treatment of cancer.
Adams J
Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
[TBL] [Abstract][Full Text] [Related]
9. Development of the proteasome inhibitor Velcade (Bortezomib).
Adams J; Kauffman M
Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition in cancer: development of PS-341.
Adams J
Semin Oncol; 2001 Dec; 28(6):613-9. PubMed ID: 11740819
[TBL] [Abstract][Full Text] [Related]
11. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
12. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma.
Amiri KI; Horton LW; LaFleur BJ; Sosman JA; Richmond A
Cancer Res; 2004 Jul; 64(14):4912-8. PubMed ID: 15256463
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
15. Clinical update: proteasome inhibitors in solid tumors.
Lenz HJ
Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
17. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
[TBL] [Abstract][Full Text] [Related]
18. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Lara PN; Bold RJ; Mack PC; Davies AM; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S67-71. PubMed ID: 16250931
[TBL] [Abstract][Full Text] [Related]
20. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
